Phaseline

Companies › Alasht Pharmed

Alasht Pharmed: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Canvert-M
Topical cannabidiol with essential oils (peppermint, lavender, rosemary, eucalyptus, winte
CNR1, CNR2Phase 4Migraine Disorders–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07093138Canvert-MPhase 4Migraine DisordersNeurologySep 2025

Targets

CNR1 (1) CNR2 (1)

Companies with the same targets

IGC Pharma Zynerba Pharmaceuticals Bazelet Nehushtan Incannex Healthcare Vertanical Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix

Companies built like this

Sound Wave Innovation NeuroTherapia Navamedic Danyang Huichuang Medical Equipment Dyne Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.